Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,190,213 papers from all fields of science
Search
Sign In
Create Free Account
KW 2307
Known as:
KW-2307
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Vinorelbine tartrate
Broader (1)
vinorelbine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells.
Kazuya Fukuoka
,
H. Arioka
,
+9 authors
Kazuto Nishio
Lung Cancer
2001
Corpus ID: 43408246
1995
1995
[A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].
K. Furuse
,
S. Yamori
,
+7 authors
N. Katakami
Gan to kagaku ryoho. Cancer & chemotherapy
1995
Corpus ID: 20760879
1994
1994
[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group].
H. Niitani
,
K. Furuse
,
M. Fukuoka
,
K. Hasegawa
,
T. Taguchi
Gan to kagaku ryoho. Cancer & chemotherapy
1994
Corpus ID: 20058044
Phase I study on a new vinca alkaloid derivative, KW-2307(vinorelbine), was conducted by multiple institutions in 40 patients…
Expand
1994
1994
Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice
T. Tsuruo
,
M. Inaba
,
+6 authors
K. Gomi
Anti-Cancer Drugs
1994
Corpus ID: 26411112
The In vitro antitumor activity of navelbine (NVB, KW- 2307), a newly synthesized vlnca alkaloid, was compared with that of…
Expand
1994
1994
[Early phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section].
T. Tominaga
,
Y. Nomura
,
+7 authors
Y. Kunii
Gan to kagaku ryoho. Cancer & chemotherapy
1994
Corpus ID: 10329068
A multi-institutional early phase II study of KW-2307 (vinorelbine), a new vinca alkaloid derivative, in advanced or recurrent…
Expand
1994
1994
[Phase-I clinical study of KW-2307 combined with cisplatin in non-small cell lung cancer patients].
Masayuki Yamamoto
,
Yutaka Ariyoshi
,
+6 authors
H. Niitani
Gan to kagaku ryoho. Cancer & chemotherapy
1994
Corpus ID: 29604805
A phase-I clinical study with coadministration of a new vinca alkaloid derivative KW-2307 with cisplatin (CDDP) at 80 mg/m2 to…
Expand
1994
1994
[Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section)].
T. Tominaga
,
Y. Nomura
,
+7 authors
S. Takashima
Gan to kagaku ryoho. Cancer & chemotherapy
1994
Corpus ID: 24061534
A multi-institutional late phase II study of KW-2307 (vinorelbine), a new vinca alkaloid derivative, in advanced or recurrent…
Expand
1993
1993
Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice
T. Ashizawa
,
Masao Asada
,
Elji Kobayashi
,
M. Okabe
,
K. Gomi
,
T. Hirata
Anti-Cancer Drugs
1993
Corpus ID: 24123674
The in vivo combination effect of navelbine (NVB, KW-2307) plus cisplatin was compared with that of vindesine (VDS) plus…
Expand
1993
1993
Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.
K. Gomi
,
H. Ohno
,
K. Nomura
,
M. Okabe
,
K. Kobayashi
,
H. Niitani
Japanese journal of cancer research : Gann
1993
Corpus ID: 13715391
1992
1992
Kinetic Analysis of Combination Effect of Navelbine (KW‐2307) with Cisplatin against Human Lung Adenocarcinoma PC‐12 Cells in Culture
K. Gomi
,
H. Ohno
,
K. Nomura
,
M. Okabe
,
K. Kobayashi
,
H. Niitani
Japanese Journal of Cancer Research : Gann
1992
Corpus ID: 72236507
The combination effect of navelbine (NVB, KW‐2307), a newly synthesized vinca alkaloid, and cisplatin (CDDP) was compared with…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE